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Background: Olodaterol is a novel, inhaled long-acting β2-agonist (LABA) with >24-h duration of action
investigated in asthma and chronic obstructive pulmonary disease.
Methods: Two multicentre studies examined the efficacy and safety of 4 weeks’ once-daily (QD) olodaterol (2, 5, 10 and
20 μg, with background inhaled corticosteroids) in patients with asthma. One randomised, double-blind, parallel-group
study (1222.6; 296 patients) administered treatment in the morning. Pulmonary function tests (PFTs) were performed
pre-dose (trough) and ≤3 h post-dose (weeks 1 and 2), and ≤6 h post-dose after 4 weeks; primary end point was trough
forced expiratory volume in 1 s (FEV1) response (change from baseline mean FEV1) after 4 weeks. A second randomised,
double-blind, placebo- and active-controlled (formoterol 12 μg twice daily) incomplete-block crossover study (1222.27;
198 patients) administered QD treatments in the evening. PFTs were performed over a 24-h dosing interval after 4 weeks;
primary end point was FEV1 area under the curve from 0–24 h (AUC0–24) response (change from study baseline [mean
FEV1] after 4 weeks).
Results: Study 1222.6 showed a statistically significant increase in trough FEV1 response with olodaterol 20 μg (0.147 L;
95 % confidence interval [CI]: 0.059, 0.234; p = 0.001) versus placebo, with more limited efficacy and no evidence of dose
response compared to placebo across the other olodaterol doses (2, 5 and 10 μg). Study 1222.27 demonstrated increases
in FEV1 AUC0–24 responses at 4 weeks with all active treatments (p < 0.0001); adjusted mean (95 % CI) differences from
placebo were 0.140 (0.097, 0.182), 0.182 (0.140, 0.224), 0.205 (0.163, 0.248) and 0.229 (0.186, 0.272) L for olodaterol 2, 5, 10
and 20 μg, respectively, and 0.169 (0.126, 0.211) for formoterol, providing evidence of increased efficacy with higher
olodaterol dose. Olodaterol was generally well tolerated, with a few events associated with known sympathomimetic
effects, mainly with 20 μg.
Conclusions: The LABA olodaterol has >24-h duration of action. In patients with asthma, evidence of bronchodilator
efficacy was demonstrated with statistically and clinically significant improvements in the primary end point of trough
FEV1 response measured in clinics over placebo for the highest administered dose of 20 μg in Study 1222.6, and
statistically and clinically significant improvements versus placebo in FEV1 AUC0–24 responses at 4 weeks for all doses
tested in Study 1222.27, which also exhibited a dose response. Bronchodilator efficacy was seen over placebo for all
olodaterol doses for morning and evening peak expiratory flow in both studies. All doses were well tolerated.
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Trial registrations: NCT00467740 (1222.6) and NCT01013753 (1222.27).
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The use of inhaled long-acting β2-agonists (LABAs) is
recommended in asthma guidelines as add-on to inhaled
corticosteroids (ICS) and has been shown to improve
lung function and reduce symptoms and future risk of
severe exacerbations [1–3]. Twice-daily (BID) LABAs
such as formoterol and salmeterol are well-established
controllers in asthma as add-on to ICS [2] and fixed-
dose combination products have been available for a
number of years. The development of once-daily (QD)
LABAs for the treatment of asthma may simplify the
dosing strategy and potentially improve adherence and
outcomes [4–6].
Olodaterol is a novel LABA with 24-h bronchodilatory
activity and is characterised by high β2 selectivity and
almost full agonist activity at β2 adrenoreceptors [7, 8].
Initial single-dose studies in asthma and chronic ob-
structive pulmonary disease (COPD) have provided clin-
ical evidence of ≥24-h activity. In patients with asthma,
olodaterol was evaluated in a single-dose study that
showed significant protection against methacholine
bronchoconstriction compared to placebo for ≤32 hours
[9]. In COPD, a Phase II, clinical, single-dose study
showed that QD olodaterol effectively maintained bron-
chodilation over 24 h [10–12]. Olodaterol has recently
been approved at a dose of 5 μg QD for use as mainten-
ance treatment for patients with COPD in Europe
and the USA, supported by data from the Phase III
olodaterol clinical trial programme that established
the long-term efficacy of QD olodaterol for lung-
function improvement [13–16].
To further assess the optimum dose of olodaterol in
patients with asthma, two dose-finding studies with dif-
ferent designs were conducted sequentially. Both studies
aimed to determine the optimum dose of olodaterol in-
halation solution delivered by the Respimat® inhaler QD
for 4 weeks in patients with asthma. The first study used
a parallel-treatment-group design and the second was
conducted using an incomplete-block crossover design.
Both studies were randomised and double blind. Data
from these studies have previously been presented at the
American Thoracic Society Annual Meeting [17, 18].
Methods
Study design
Study 1222.6 was a multicentre, randomised, double-
blind, placebo-controlled, parallel-group study to assess
the efficacy and safety of 4 weeks of treatment withorally inhaled olodaterol 2, 5, 10 and 20 μg delivered via
Respimat® device QD (in the morning) in patients with
asthma to determine the optimum dose and confirm
24-h bronchodilation with this posology (Fig. 1a).
Study 1222.27 was a multicentre, randomised, double-
blind, double-dummy, active- and placebo-controlled,
incomplete-block crossover study to determine the effi-
cacy and safety of four different doses of olodaterol (2, 5,
10 and 20 μg) delivered by the Respimat® device QD in
the evening versus BID formoterol (12 μg) delivered by
the Aerolizer® inhaler and matching placebo for 4 weeks
in patients with asthma (Fig. 1b). The 16-week treatment
phase comprised four 4-week treatment periods without
intervening washout periods, with efficacy end points
being assessed after 4 weeks of each treatment at study
centre visits.
For Study 1222.6, it was estimated that a sample size
of 60 patients per treatment group was required to de-
tect with ≥90 % power a difference of 0.15 L from pla-
cebo in the primary end point (trough forced expiratory
volume in 1 s [FEV1] response) at the 5 % significance
level.
For Study 1222.27, a sample size of approximately
190 patients was planned to detect a difference from pla-
cebo of 0.1 L with 95 % power for a single treatment com-
parison (assuming a standard deviation for the paired
differences of 0.25 L), allowing for the loss of efficiency
caused by the incomplete-block crossover design, for
patient attrition and in order to achieve a balanced design.
Further details of study designs, assessments per-
formed, key inclusion and exclusion criteria, and statis-
tical methodologies are detailed in Additional file 1:
Tables S1 and S2.
Both studies were performed in accordance with the
principles laid down by the Declaration of Helsinki,
International Committee on Harmonisation, Good Clinical
Practice Guidelines, European Medical Device Directive
and local regulations. Prior to initiation of the studies,
the protocols were approved by the ethics research
boards of the respective institutions and written, in-
formed consent was obtained from all patients. Both
studies were registered with ClinicalTrials.gov (Study
1222.6: NCT00467740; Study 1222.27: NCT01013753).
End points
The primary end point for Study 1222.6 was trough
FEV1 response (response being defined as change from
study baseline mean FEV1) at 4 weeks. Secondary and
(a)
(b)
Fig. 1 Designs of studies: (a) 1222.6 and (b) 1222.27. QD: once daily; BID: twice daily; ICS: inhaled corticosteroid
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from 0–3 h (AUC0–3) response (response defined as
change from study baseline FEV1) after the first dose
and after 1, 2 and 4 weeks of treatment, weekly mean
pre-dose morning peak expiratory flow (PEF) response
(patient diaries), weekly mean evening PEF response,
total score on the Asthma Control Questionnaire (ACQ)
and safety.
The primary end point for Study 1222.27 was FEV1
area under the curve from 0–24 h (AUC0–24) response
(defined as change from study baseline mean FEV1) after
4 weeks of treatment. Secondary and other end pointsincluded FEV1 at individual time points over 24 h post-
dose, trough and peak FEV1 responses at the end of each
4-week treatment period, weekly pre-dose PEF (from the
patient diaries), control of asthma as assessed by total
score on the ACQ and quality of life as assessed by the
standardised version of the Asthma Quality of Life
Questionnaire (AQLQ[S]) at the end of the treatment
period.
For both studies, pulmonary function tests (PFTs)
were conducted at screening and baseline. In Study
1222.6 (parallel-group design), PFTs were conducted at
1 h and at 10 min before the morning dose and 30 min,
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ment and after 1, 2 and 4 weeks of randomised treat-
ment. This was extended to 4, 5 and 6 h post-dosing at
the final treatment visit. PFTs were also conducted at
follow-up.
In Study 1222.27 (incomplete-block crossover design),
PFTs were performed at screening, at the end of the 2-
week baseline period, after 4 weeks of each randomised
treatment and at follow-up. At the baseline visit, two
PFTs were performed at 1 h and at 10 min prior to the
first evening dose of study medication. At the end of
each 4-week treatment period, PFTs were performed at
1 h and at 10 min before the evening dose and at de-
fined time points within 24 h post-dosing (30 min, 1, 2,
3, 4 h, 11 h 50 min, 12 h 30 min, 13, 14, 15, 16, 18, 20,
22, 23 h and 23 h 50 min post-dose). A single PFT was
performed at the follow-up visit.
Results
In Study 1222.6, a total of 296 patients were rando-
mised to treatment at 37 centres and 289 patients
completed the study (Fig. 2a), while in Study 1222.27,
198 patients were randomised at 27 centres and
182 patients completed the study (Fig. 2b). Across the
studies, demographic characteristics were generally
similar (Tables 1 and 2). Mean ages in Study 1222.6
ranged between 43.6 and 46.3 years across the treat-
ment groups, while in Study 1222.27 the mean age
was 45.0 years; across the studies there were slightly
more women than men. The majority of patients were
never smokers.
In Study 1222.6, for the primary end point of trough
FEV1 response after 4 weeks of treatment, there was a
similar degree of improvement compared with placebo
for the 2, 5 and 10 μg doses of olodaterol: mean (95 %
confidence interval [CI]) difference of 0.080 (−0.008,
0.167) for the 2 μg olodaterol treatment group, 0.086
(−0.003, 0.174) for the 5 μg treatment group and 0.076
(−0.012, 0.164) for the 10 μg group. The differences be-
tween the 20 μg dose and placebo were largest and sta-
tistically significant: mean (95 % CI) 0.147 (0.059, 0.234;
p = 0.0011) (Fig. 3a and Additional file 1: Table S3).
There was no evidence of a dose–response relationship
across the 2, 5 and 10 μg doses of olodaterol (Add-
itional file 1: Table S3), with similar results for trough
FEV1 response observed at weeks 1 and 2 (Fig. 3a).
Figure 3b shows FEV1 at individual time points up to
3 h post-dose at week 4 in Study 1222.6; with olodaterol
20 μg these were statistically significant (p < 0.001) at all
time points. Values for FEV1 AUC0–3 response were also
statistically significantly (p < 0.05) higher in each of the
olodaterol treatment groups compared to placebo at
weeks 1, 2 and 4 (Fig. 3c). For both FEV1 over time at
week 4 and FEV1 AUC0–3 at weeks 1, 2 and 4, the samepattern was observed as for the primary end point, with
little separation between the 2, 5 and 10 μg doses.
A different pattern was observed for other secondary
end points, with some evidence of a dose–response rela-
tionship apparent for the mean change in weekly morn-
ing pre-dose PEF from baseline (Table 3). Similar results
were apparent for the evening PEF response (Table 3).
After 4 weeks of treatment, mean total ACQ scores also
decreased from baseline in each of the active treatment
groups, although the changes compared with placebo
were only statistically significant (p < 0.05) in the oloda-
terol 10 and 20 μg dose groups. The mean (95 % CI)
differences compared to placebo were −0.142 with 2 μg
(−0.368, 0.083; p = 0.216), −0.197 with 5 μg (−0.422, 0.029;
p = 0.087), −0.328 with 10 μg (−0.552, −0.103; p = 0.004)
and −0.276 with 20 μg (-0.499, −0.052; p = 0.016).
In Study 1222.27, the mean FEV1 AUC0–24 response
after 4 weeks of treatment was highly statistically signifi-
cantly different compared to placebo for all doses of olo-
daterol and formoterol (p < 0.0001) (Additional file 1:
Table S4), with a clear dose–response relationship in the
treatment effect for olodaterol. The adjusted mean (95 %
CI) FEV1 AUC0–24 response differences from placebo
after 4 weeks of treatment were 0.140 (0.097, 0.182),
0.182 (0.140, 0.224), 0.205 (0.163, 0.248) and 0.229
(0.186, 0.272) L for 2, 5, 10 and 20 μg olodaterol, re-
spectively; the adjusted mean difference from placebo
with formoterol was 0.169 (0.126, 0.211) L.
Differences in adjusted mean FEV1 at each individual
time point over the 24-h period also demonstrated a
clear dose–response relationship (Fig. 4). There were
highly statistically significant (p < 0.0001) improvements
in trough and peak FEV1 responses at week 4, again with
dose–response relationships apparent with olodaterol
(Additional file 1: Table S5).
While there were significant differences in adjusted
mean weekly morning PEF and evening PEF (home-
measured) at week 4 for all doses of olodaterol and
formoterol compared to placebo (p < 0.0001), the in-
creases with olodaterol did not show the same dose–
response relationship as the in-clinic visit FEV1 end
points (Additional file 1: Table S6). There were statis-
tically significant reductions in mean total ACQ scores
with all active treatments during the study; however, there
was no clear dose ordering between the 2, 5 and 10 μg
doses. At week 4, the mean (95 % CI) differences
compared to placebo were −0.321 (−0.432, −0.210)
with the 2 μg dose, −0.293 (−0.403, −0.184) with the
5 μg dose, −0.326 (−0.436, −0.215) with the 10 μg
dose and −0.394 (−0.505, −0.282) with the 20 μg dose; all
differences were highly statistically significant (p < 0.0001).
Compared to placebo, the mean (95 % CI) difference with
formoterol was −0.346 (−0.457, −0.235; p < 0.0001). There
were also statistically significant increases in AQLQ(S)
Fig. 2 Patient disposition in studies: (a) 1222.6 and (b) 1222.27
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Age, mean (SD), years 43.6 (14.1) 45.4 (15.1) 46.2 (13.0) 46.3 (14.5) 44.6 (13.0)
Male, n (%) 20 (37.0) 22 (36.1) 30 (50.0) 26 (43.3) 28 (45.9)
Asthma diagnosis, mean (SD), years 23.7 (13.3) 19.8 (13.8) 23.3 (15.6) 22.5 (15.5) 22.9 (16.2)
Body mass index, mean (SD), kg/m2 28.6 (7.2) 27.0 (6.1) 28.8 (6.85) 26.5 (5.2) 27.3 (5.81)
Smoking status, n (%)
Current smoker 3 (5.6) 7 (11.5) 2 (3.3) 2 (3.3) 2 (3.3)
Ex-smoker 10 (18.5) 16 (26.2) 10 (16.7) 14 (23.3) 15 (24.6)
Never smoker 41 (75.9) 38 (62.3) 48 (80.0) 44 (73.3) 44 (72.1)
Smoking history, mean (SD), pack-yearsa 3.6 (2.4) 4.8 (2.7) 5.5 (2.8) 5.9 (2.7) 3.4 (2.6)
Pre-bronchodilator FEV1, mean (SD), L 2.30 (0.62) 2.31 (0.74) 2.39 (0.61) 2.32 (0.64) 2.37 (0.60)
Post-bronchodilator FEV1, mean (SD), L 2.72 (0.70) 2.76 (0.91) 2.79 (0.70) 2.74 (0.70) 2.82 (0.69)
Change in FEV1 from pre-bronchodilator (SD), L 0.43 (0.15) 0.44 (0.23) 0.41 (0.13) 0.42 (0.16) 0.44 (0.15)
Post-bronchodilator FEV1:FVC ratio, mean (SD), % 74.3 (7.4) 75.1 (9.5) 74.2 (7.2) 73.6 (8.5) 74.3 (7.4)
aBased on n = 13 for placebo, 23 for 2 μg, 12 for 5 μg, 16 for 10 μg, and 17 for 20 μg (i.e. only current and ex-smokers were included in this analysis)
SD: standard deviation; FEV1: forced expiratory volume in 1 s; FVC: forced vital capacity
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placebo (p < 0.001). Mean (95 % CI) differences to placebo
were 0.289 (0.178, 0.400) with olodaterol 2 μg, 0.209
(0.099, 0.318) with the 5 μg dose, 0.262 (0.151, 0.374) with
the 10 μg dose, 0.317 (0.205, 0.429) with the 20 μg dose
and 0.315 (0.203, 0.426) with formoterol.
The incidence of adverse events in Study 1222.6
was 37.7 %, 40.0 %, 30.0 %, 39.3 % and 27.8 % in
patients receiving olodaterol 2 μg, 5 μg, 10 μg, 20 μg
and placebo, respectively (Additional file 1: Table S7).
Exacerbation of asthma occurred at a higher in-
cidence in the placebo treatment group (7.4 %Table 2 Baseline patient demographic details in Study 1222.27
Total (n = 198)
Age, mean (SD), years 45.0 (11.8)
Male, n (%) 86 (43.4)
Asthma diagnosis, mean (SD), years 20.4 (13.2)
Body mass index, mean (SD), kg/m2 27.9 (5.3)
Smoking status, n (%)
Current smoker 1 (0.5)
Ex-smoker 51 (25.8)
Never smoker 146 (73.7)
Smoking history, mean (SD), pack-yearsa 5.4 (2.7)
Pre-bronchodilator FEV1, mean (SD), L 2.37 (0.63)
Post-bronchodilator FEV1, mean (SD), L 2.92 (0.79)
Change in FEV1 from pre-bronchodilator (SD), L 0.55 (0.30)
Post-bronchodilator FEV1:FVC ratio, mean (SD), % 71.9 (8.8)
aBased on n = 52 (i.e. only current and ex-smokers were included in
this analysis)
SD: standard deviation; FEV1: forced expiratory volume in 1 s; FVC: forced
vital capacitycompared to 1.7–3.3 % in the olodaterol groups).
Only 24 adverse events (total: all treatment groups)
were considered drug related, the most common be-
ing tremor, headache, dizziness, palpitations and anx-
iety. However, there was a higher number of patients
with drug-related adverse events in the olodaterol
20 μg group compared to the lower-dose groups
(16.4 % compared to 3.3–8.3 % in the other groups),
the most frequent being tremor.
One patient receiving olodaterol 5 μg was withdrawn
from Study 1222.6 due to an adverse event of premature
ventricular contractions. Two patients experienced at
least one serious adverse event during the study: one in
the 10 μg group experienced pneumonia and one in the
20 μg group experienced dizziness, palpitations, hyperhi-
drosis and chest pain, which were considered drug re-
lated. None of the serious adverse events were fatal or
life-threatening.
More female patients in the olodaterol 20 μg group
experienced drug-related adverse events (seven patients;
21.2 %) than in the placebo group (two patients; 5.1 %)
or other active treatment groups (one to three patients;
3.3–8.8 %). No such difference was seen for male patients.
Changes in vital signs, electrocardiogram and labora-
tory parameters in line with known systemic sympatho-
mimetic effects were observed in Study 1222.6 with
olodaterol doses ≥10 μg, with increased heart rate,
shortened uncorrected QT interval, increased QT
(Bazett corrected) and T-wave abnormalities. Although
there was a statistically significant reduction in mean
serum potassium levels in patients with the 20 μg olo-
daterol dose compared to placebo following treatment
on day 1 (4.18 versus 4.38 mmol/L; p = 0.0006), no
Fig. 3 FEV1 assessments in Study 1222.6. (a) Trough FEV1 response weeks 1–4 from baseline (±SE), (b) FEV1 profile over time at week 4 from
baseline (±SE) and (c) FEV1 AUC0–3 response weeks 1–4 from baseline (±SE). FEV1: forced expiratory volume in 1 s; SE: standard error; AUC0–3: area
under the curve from 0–3 h
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placebo and any active treatment dose groups were
observed at other time points during the study. Two
electrocardiogram results were reported as adverse
events: one patient in the placebo group with an
atrioventricular block and one in the 5 μg group with
ventricular extrasystoles.The overall incidence of adverse events in Study
1222.27 was 9.9 %, 13.8 %, 15.7 %, 12.9 %, 6.4 % and
4.8 % in patients receiving olodaterol 2 μg, 5 μg, 10 μg,
20 μg, formoterol and placebo, respectively. The differ-
ences in overall adverse event incidences between treat-
ments could not be explained by more frequent
occurrences of any particular preferred term. Only three
Table 3 Weekly pre-dose morning and evening PEF response
(L/min) after 4 weeks of treatment for Study 1222.6
n Difference from placebo
Mean (SE) Mean (SE) 95 % CI p value
Morning PEF
Placebo 54 368.18 (5.71)
Olodaterol 2 μg 61 384.42 (5.38) 16.24 (7.84) 0.80, 31.68 0.0393
Olodaterol 5 μg 60 396.06 (5.42) 27.88 (7.88) 12.38, 43.38 0.0005
Olodaterol 10 μg 59 404.26 (5.47) 36.07 (7.91) 20.51, 51.63 <0.0001
Olodaterol 20 μg 61 411.13 (5.38) 42.94 (7.85) 27.50, 58.39 <0.0001
Evening PEF
Placebo 54 384.08 (5.59)
Olodaterol 2 μg 61 407.05 (5.26) 22.97 (7.67) 7.88, 38.06 0.0030
Olodaterol 5 μg 60 408.68 (5.30) 24.60 (7.70) 9.45, 39.75 0.0016
Olodaterol 10 μg 59 420.88 (5.34) 36.81 (7.73) 21.60, 52.02 <0.0001
Olodaterol 20 μg 61 426.58 (5.26) 42.51 (7.68) 27.40, 57.61 <0.0001
PEF: peak expiratory flow; SE: standard error; CI: confidence interval
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treatment: nasopharyngitis, dyspnoea and headache
(Additional file 1: Table S8). Two patients experienced
serious adverse events: one patient being treated with
10 μg experienced appendicitis and one patient in the
post-treatment period (last treatment olodaterol 2 μg)
had a cerebral infarction. Both patients recovered (the
patient with cerebral infarction recovered with sequelae)Fig. 4 FEV1 assessments in Study 1222.27: adjusted mean FEV1 trough resp
function test; FEV1: forced expiratory volume in 1 sand neither serious adverse event was considered drug
related.
Eight adverse events were considered related to study
drug in Study 1222.27: four with olodaterol 5 μg (can-
didiasis, headache, palpitations and muscle spasms), two
with olodaterol 10 μg (palpitations and muscle spasms)
and one each with olodaterol 2 μg (insomnia) and pla-
cebo (metrorrhagia). No drug-related adverse events
were reported by patients being treated with 20 μg olo-
daterol or formoterol.
With the exception of olodaterol 20 μg, there was
generally a greater percentage of female patients report-
ing at least one adverse event with olodaterol treatment:
11.4 % (2 μg), 18.3 % (10 μg), 22.2 % (15 μg) and
12.7 % (20 μg) with olodaterol compared to 4.1 % with
placebo and 5.8 % with formoterol. This is in compari-
son to 7.8 % (2 μg), 12.5 % (10 μg), 3.4 % (15 μg) and
13.2 % (20 μg) of male patients following olodaterol
treatment and 5.8 % and 7.1 % following treatment with
placebo or formoterol, respectively.
Analysis of the electrocardiogram results showed that,
compared to placebo, there was a slight increase (mean
change from baseline: 4.23 ms at 1 h) in the mean
Fridericia-corrected QT interval with 20 μg olodaterol.
There were statistically significant (p < 0.03) reductions in
mean blood potassium concentration seen 1 h post-dose:
ratios of geometric mean olodaterol:placebo (95 % CI)
were 0.979 (0.962, 0.997) with 5 μg, 0.977 (0.960, 0.995)onse at week 4. QD: once daily; BID: twice daily; PFT: pulmonary
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however, these changes were not considered to be clinic-
ally relevant.
One electrocardiogram result was reported as an ad-
verse event: one patient with an atrioventricular block
while receiving olodaterol 20 μg and formoterol.
Discussion
These studies have demonstrated that olodaterol is an
inhaled LABA with a duration of effect lasting >24 h in
patients with asthma when administered in addition to
ICS over 4 weeks, as measured by improvements over
placebo in FEV1 and home-measured morning and even-
ing PEF in both studies. Olodaterol also improved symp-
toms as measured by a reduction in ACQ scores. Both
studies demonstrated or indicated dose–response ef-
fects of olodaterol to a greater (Study 1222.27) or
lesser (Study 1222.6) degree across the 2, 5, 10 and
20 μg doses used. The outcome variables that indicated
olodaterol dose response in the two studies varied, be-
ing indicated only by secondary end points of weekly
morning and evening PEF in Study 1222.6, and by the
primary end point of FEV1 AUC0–24 response and sec-
ondary end points of trough, peak and individual time
point FEV1 responses in Study 1222.27 (as well as
other end points studied in 1222.27).
Potential reasons for the differences in the outcome
variables demonstrating dose response between the stud-
ies could include the populations and/or the designs
used in the two studies. However, the study populations
were similar with regards to patient demographics; all
patients were taking ICS and both populations demon-
strated a dose response to olodaterol in some outcome
variables. Therefore, it is unlikely that an important dif-
ference in patient characteristics is an adequate explan-
ation. By contrast, the study designs used were very
different. Study 1222.6 used a parallel-group design and
Study 1222.27 an incomplete-block crossover design,
with each patient receiving four out of a possible six
treatments and acting as their own controls for the
dose–response evaluations and an active comparator
with formoterol. Another important difference in the de-
sign of the studies was the time of administration of olo-
daterol: in the morning in Study 1222.6 and in the
evening in Study 1222.27.
Another study that examined the dose–response char-
acteristics of olodaterol was also a crossover design and
included patients with milder asthma, not taking ICS.
The primary outcome variable was change in methacho-
line provocative concentration causing a 20 % fall in
FEV1 (PC20). Olodaterol demonstrated a clear dose re-
sponse for the changes in methacholine PC20 [9].
There are challenges in conducting β2-agonist dose–
response studies in asthma. Studies examining the doseresponse of β2-agonists using bronchoprovocation
models in asthma are inherently easier to conduct, as
they involve mild, stable patients with close to normal
baseline FEV1 values. When indices of bronchodilation
are used to measure effect, the patients need to have
baseline airflow obstruction in order to demonstrate a
response and in most countries such patients would be
treated with ICS. These patients may also be previously
treated with LABA and washed out from this medica-
tion (for a minimum of 2 weeks in Study 1222.6 and
48 h in Study 1222.27).
Other LABAs with a duration of action of >24 h have
been studied in patients with asthma. Beeh et al. demon-
strated that indacaterol had a duration of bronchodila-
tion of 24 h for the two highest doses but did not
demonstrate a significant dose response for FEV1 across
four doses administered [19]. Another study that in-
cluded patients taking ICS and which evaluated four
doses of indacaterol treatment for 7 days also did not
demonstrate a dose response when FEV1 was measured
[20]. The dose–response characteristics of vilanterol, an-
other LABA, have been evaluated in patients with
asthma taking ICS measured by treating with five differ-
ent doses for 28 days and measuring both FEV1 and PEF
[21]. Once again, while prolonged bronchodilation was
observed for the three highest doses used, a significant
dose response was not seen for either outcome variable.
These studies demonstrate the challenges in document-
ing a clear dose response for a LABA seen in a primary
end-point measure (as in Study 1222.27), although evi-
dence for a dose response may be apparent in secondary
end-point measures (as in Study 1222.6).
The safety profile of olodaterol was as expected for all
β2-agonists, with tremor and changes in serum potassium
and the QT interval in the electrocardiogram at the high-
est dose. There was no evidence of an increase of severe
adverse events with olodaterol when compared to placebo
in Study 1222.6 or formoterol in Study 1222.27.
These studies did have some limitations in that neither
study was adequately powered to identify differences
between the different doses of active treatments (both
studies were powered for comparisons between oloda-
terol and placebo), though this is not unusual for
Phase II dose-finding studies.
When taken together, the weight of the evidence from
several olodaterol trials in asthma indicates a relevant
dose–response relationship between a total daily dose of
5 and 10 μg olodaterol. In addition to the results from
these present studies, further evidence has been pro-
vided by a study examining the 24-h FEV1 time profile
after 3 weeks of treatment with QD or BID regimens of
olodaterol (at the same total daily dose) versus placebo
(NCT01311661; 1222.29). Dose responses, although not
the primary objective of the studies, were consistently
O’Byrne et al. Respiratory Research  (2015) 16:97 Page 10 of 11observed for a total daily dose of 5 versus 10 μg oloda-
terol (Beeh et al., manuscript in preparation).
In conclusion, treatment with olodaterol QD for
4 weeks was well tolerated at all doses and no new safety
concerns were identified, although some sympatho-
mimetic effects were observed, mainly at the 20 μg dose.
Parallel, as well as incomplete-block crossover, designs
may be suitable for Phase II dose-ranging studies and
more than one study may be necessary to strengthen the
evidence for a dose response.
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